LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

MRK

115.35

-2.1%↓

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

MRK

115.35

-2.1%↓

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

MRK

115.35

-2.1%↓

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

MRK

115.35

-2.1%↓

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

MRK

115.35

-2.1%↓

Inicio・Lista de Acciones・AbbVie Inc

AbbVie Inc

Cerrado

Sector Salud

196.25 1.59

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

193.18

Máximo

196.59

Métricas clave
By Trading Economics
Ingresos	1M 1.4B
Ventas	2.2B 14B
P/B Media del Sector	51.05 103.001
BPA	2.65
Margen de beneficio	9.474
Empleados	50,000
EBITDA	514M 5B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+2.24 upside

Dividendos
By Dow Jones
Próximas Ganancias	25 oct 2024
Fecha Próximo Dividendo	15 nov 2024
Próxima Fecha de Ex Dividendo	15 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	348B
Apertura anterior	194.66
Cierre anterior	196.25

Noticias sobre sentimiento de mercado

By Acuity

50%

100 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

192.16 / 196.2271 Soporte y Resistencia

AbbVie Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

25 jul 2024, 12:18 UTC

Ganancias

AbbVie 2Q Revenue Gets Boost From Skyrizi, Rinvoq Sales

27 jun 2024, 13:58 UTC

Adquisiciones, fusiones, absorciones

AbbVie Buys Celsius Therapeutics for $250 Million

26 abr 2024, 20:53 UTC

Principales Movimientos del Mercado

AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q

26 abr 2024, 12:25 UTC

Ganancias

AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises

3 sept 2024, 04:00 UTC

Principales Noticias

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

12 ago 2024, 14:30 UTC

Adquisiciones, fusiones, absorciones

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12 ago 2024, 09:30 UTC

Principales Noticias

Adquisiciones, fusiones, absorciones

Big Drugmakers Are Clinching Smaller Deals -- WSJ

1 ago 2024, 12:23 UTC

Adquisiciones, fusiones, absorciones

AbbVie Completes Acquisition Of Cerevel Therapeutics >ABBV CERE

29 jul 2024, 10:30 UTC

Principales Noticias

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

25 jul 2024, 13:01 UTC

Ganancias

AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance -- IBD

25 jul 2024, 12:46 UTC

Principales Noticias

Ganancias

AbbVie Stock Is Rising on Strong Earnings. CEO Cites 'Significant Momentum.' -- Barrons.com

25 jul 2024, 11:36 UTC

Ganancias

AbbVie Sees FY Adj EPS $10.71-Adj EPS $10.91 >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q EPS 77c >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Rev $14.46B >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Global Skyrizi Rev $2.73B >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q U.S. HUMIRA Rev $2.36B >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q International HUMIRA Rev $454M >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Adj EPS $2.65 >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Net $1.37B >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Global IMBRUVICA Rev $833M >ABBV

25 jul 2024, 08:40 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Ford, Tesla, Alphabet, Nvidia, Super Micro, IBM, ServiceNow, Chipotle, and More -- Barrons.com

27 jun 2024, 13:28 UTC

Adquisiciones, fusiones, absorciones

AbbVie Acquires Celsius for $250 Million in Cash >ABBV

27 jun 2024, 13:28 UTC

Adquisiciones, fusiones, absorciones

AbbVie: Celsius' Lead Asset Has Completed Phase 1 Study in Inflammatory Bowel Disease >ABBV

27 jun 2024, 13:26 UTC

Adquisiciones, fusiones, absorciones

AbbVie Acquires Celsius Therapeutics >ABBV

23 may 2024, 20:05 UTC

Adquisiciones, fusiones, absorciones

AbbVie Completes Acquisition Of Landos Biopharma >ABBV LABP

7 may 2024, 20:30 UTC

Principales Noticias

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

26 abr 2024, 13:03 UTC

Ganancias

AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title -- IBD

26 abr 2024, 12:04 UTC

Ganancias

AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop -- Barrons.com

26 abr 2024, 11:41 UTC

Ganancias

AbbVie 1Q Adjusted EPS Cut 8c by Acquired IPR&D, Milestones Expense >ABBV

Comparación entre iguales

Cambio de precio

AbbVie Inc Esperado

Precio Objetivo

By TipRanks

2.24% repunte

Estimación a 12 meses

Media 197.73 USD 2.24%

Máximo 218 USD

Mínimo 170 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbbVie Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

15 ratings

Comprar

Mantener

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para AbbVie Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

192.16 / 196.2271Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bullish event.

Sentimiento

By Acuity

100 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.